In addition to lipid-lowering therapies, the CKM advisory recommends selecting cardioprotective antihyperglycemic agents among those with diabetes, and SGLT2 inhibitors (SGLT2i) for those with CKD, existing heart failure, or those at high risk of heart failure [35,36]. This evidence concerns the gene SLC5A2 and heart failure.